The SAPA-CT 11th Annual Meeting took place at Yale University on December 7, 2024, under the theme “New Era of Innovation in Biomedicine.” The event was packed with insightful discussions on:🔹 Cutting-edge drug development technologies🔹 AI-driven research🔹 Career development workshops🔹…
📣 Create Your Ideal AAV Vectors Today and Accelerate Your #GeneTherapy Journey with us! 🚀 Ready to Get Started? There are 3 easy ways to design your AAV vector: 1️⃣Design Your Vector now: 🔗 Click Here to Start 2️⃣Explore the…
Our President and CEO, Daozhan Yu, along with CTO Qizhao Wang, will represent AAVnerGene at the SAPA-CT 2024 Annual Conference this Saturday at Yale University! 🚀 Don’t miss Daozhan’s presentation, “New Technologies to Enhance AAV Gene Therapy Efficiency,” happening from…
🎉AAVnerGene Inc. are excited to share that our CEO Daozhan Yu，CTO Qizhao Wang，and CBO Charles Li joined this momentous event—a Festschrift recognizing Dr. Jude Samulski’s exceptional contributions to genetherapy, AAV virology, biotechnology, and the broader #biotech industry. 💡🐾Dr. Jude Samulski‘s…
The current standard for manufacturing GMP-grade Adeo associated viral (AAV) vectors rely on a tri-plasmid system that involves transient transfection of mammalian cells with three plasmids carrying the necessary packaging components. While this method is versatile and relatively fast, scaling…
📣Our CTO, Qizhao Wang, and CBO, Charles Li, are excited to join the Advanced Therapies USA 2024 in Philadelphia this weekend! We look forward to connecting with experts, sharing insights, and exploring partnerships to drive innovation in gene therapy and…
Our President and CEO, Daozhan Yu, had the honor of moderating the CMC Panel at the Advancing Precision Mdicine Conference in Philadelphia. Panel Highlights:🔹 Industry Experts: Joined by leaders from Spark Therapeutics and CoJourney Bio🔹 Discussions: FDA’s tightening CMC quality…
Thank you all for coming by our booth at ESGCT2024 last week. We had a wonderful time connecting with experts and friends from around the world. Many were interested in several of our breakthrough technologies: 🔹 One-plasmid AAV production system,…
At the 2024 Society for Neuroscience conference, AAVnerGene and Johns Hopkins University’s Division of Neurobiology presented an innovative poster that highlights the progress in developing gene therapies for Central Nervous System (CNS) diseases. This collaborative project addresses one of the most…
AAVnerGene was excited to participate in the 2024 Society for Neuroscience (SfN) conference, one of the premier events in the neuroscience community. We were thrilled to see an overwhelming response at our booth, where we had the opportunity to engage…
